65,437 trials
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease. — 21.6; 24.9; 22.1; 12.3 titers
Coronary Artery Disease
Primary: Target Vessel Failure (TVF) — 20 participants
Degenerative Disc Disease
Primary: Rate of Overall Success — 80.9; 59.9 percentage of participants — p=<0.001
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
ST-segment Elevation Myocardial Infarction
Primary: Postinfarct Remodeling — 11; 6 Number of participants with remodeling
Kidney Cancer · Renal Cell Carcinoma
Primary: Median Time to First Skeletal-related Event — 9 months
Gastroesophageal Reflux Disease (GERD)
Primary: Number of Participants With at Most One Day With Not More Than Mild Intensity of the Symptoms 'a Burning Feeling Behind the Breastbone' and 'Unpleasant Movement of…
Dyspepsia
Primary: Gastric Emptying Half Time Measured by Scintigraphy — 65.9; 82.2 minutes
Nicotine Dependence
Primary: Biochemically Verified 7-day Point Prevalence Abstinence at the End of 8 Weeks of Treatment — 10; 13 participants
Pulmonary Hypertension
Primary: Six Minute Walk Distance (6MWD) — 339; 350; 343; 370 meters — p=0.0125
Breast Neoplasms
Primary: Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 10.2; 14.3 percentage of participants
Schizophrenia
Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score — 83.99; 53.70 scores on a scale
Glioblastoma · Gliosarcoma
Primary: 12-month Progression Free Survival (PFS) — 43.8; 34.4 percentage of participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (A1C) — -1.32; -1.42 percent
Constipation
Primary: Change of Mean Weekly Spontaneous Bowel Movements — 2; 2; 2; 2 stools/week — p=0.238